Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Apellis Pharmaceuticals to $52 from $60 and keeps a Neutral rating on the shares. The analyst updated the company’s model post the Q1 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
- Apellis announces pegcetacoplan MAA review has been reset to Day 180
- Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference